Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
For laboratory research use only
(2026, March 3)
On social media, most of the microdosing chatter is about small amounts of weight loss, perceived (but not proven!) longevity benefits, and treating many forms of inflammation
Upon activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), berberine enhances insulin sensitivity, reduces hepatic glucose output, and has been shown in animal models to increase GLP-1 secretion, although this mechanism has not yet been confirmed in large human trials
A comprehensive program plans for maintenance, not only initial loss
US$ 21.56
US$ 29.97
US$ 25.66
US$ 21.78
US$ 22.99
US$ 22.33
